Publication: CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan

Thomas R. Cox, Aug 2019

CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan

We are super excited to announce that our recent work in close collaboration with A/Prof Paul Timpson has just been published in Nature Communications (view the full Open-Access article here)

In this work (which was a large international collaboration), co-led by our team and Paul Timpson’s team (also at the Garvan Institute), we show that remodeling of the stromal  tissue in and around pancreatic tumours may be the key to stopping their spread and improving chemotherapy outcomes.

Cancer cell CAF crosstalk

What we did

We already know that tumours are made up of heterogenous populations of cancer cells with different mutational landscapes. Furthermore, recently, the field has begun to realise that the cancer associated fibroblasts (CAFs) present in and around the tumour are also a diverse collection of  subpopulations.

Continue reading

People: Amelia joins the team

Thomas R. Cox, Aug 2019

It’s with great excitement that we welcome our newest PostDoc to the team, Amelia Parker.

ameparAmelia joins us having returned from a PostDoctoral position at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in the USA. Prior to this she completed her Ph.D. in the laboratories of Professor Maria Kavallaris and A/Prof Joshua McCarroll at The Children’s Cancer Institute (CCI) in Sydney.

As a biomedical engineer and cancer biologist, Amelia is interested in the importance of the tumour microenvironment, and in particular the extracellular matrix (ECM) in driving tumour progression.

Amelia’s work will focus on the importance of the ECM in Lung Cancer onset and progression.

Publication: The Mini‐Organo: A rapid high‐throughput 3D coculture organotypic assay for oncology screening and drug development

Thomas R. Cox, Aug 2019

The Mini‐Organo: A rapid high‐throughput 3D coculture organotypic assay for oncology screening and drug development

Just published in Cancer Reports is our new protocol paper detailing the development of a rapid high-throughput (96wp) 3D organotypic coculture assay that is optimised for screening cancer cell and cancer-associated fibroblast response to drugs in physiologically relevant matrices.

Mini-Organo workflow

Continue reading

Award: Jess wins ANZSCDB Best Poster

Thomas R. Cox, Jun 2019

Jess ANZSCDB Best Poster AwardCongratulations to Jess from the team, who today won the Australia and New Zealand Society for Cell and Developmental Biology (ANZCDB) Best Postdoctoral Poster Award.

The award was given as part of the NSW State Meeting of the ANZSCDB held at the University of Sydney. Jess’ poster presented her ongoing work developing new lysyl oxidase (LOX) inhibitors to treat pancreatic cancer.

The Australia and New Zealand Society for Cell and Developmental Biology exists to promote research and education in cell and developmental biology through the provision of a dynamic framework for collaboration and support. One of Australia’s oldest Scientific Societies, the ANZSCDB supports the cell and developmental biology research community across all levels, from students to senior researchers.

You can find our more about the ANZSCDB here.

Publication: LOXL1 Is Regulated by Integrin α11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity

Thomas R. Cox, May 2019

LOXL1 Is Regulated by Integrin α11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity

Our lab has contributed to a recent paper by Zeltz and colleagues looking at the interplay between Lysyl Oxidase Like 1 (LOXL1) and Integrin α11 in Non-Small Cell Lung Cancer (NSCLC). The work was published in the Open-Access journal Cancers.

LOXL1, integrin a11 and ECM crosstalk

Continue reading

Publication: Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment

Thomas R. Cox, May 2019

Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment

A new paper has just been published revealing the role of Lysyl Oxidase Like 2 (LOXL2) in the remodelling of the prostate cancer microenvironment. The work, carried out in collaboration with lead researchers from the Cancer Program, Biomedicine Discovery Institute at Monash University has just been published in Molecular and Cellular Proteomics.

Normal Prostate Fibroblast and Cancer Associated Fibroblast proteomics

Continue reading

Funding: Cancer Council NSW Project Grant

Thomas R. Cox, Mar 2019

Cancer Council NSW grants for innovative cancer research

CCNSW Logo

Great news! The Matrix & Metastasis Lab been awarded a three-year project grant from Cancer Council NSW to explore a new combination approach to treating pancreatic cancer.

The project will look at how to target the Lysyl Oxidase (LOX) family of enzymes in in pancreatic cancer with the goal of improving outcomes in patients.

Pancreatic cancer has one of the poorest survival rates of all cancer, with only 25% of people surviving one year after diagnosis and only 8% for five years. This project will look at the tissue in and around pancreatic cancers, which can affect how successful chemotherapy treatment is in a patient.

The aim is to combining biology and engineering to generate 3D models that mimic tumours, along with cutting edge imaging technology and mouse models, to investigate the potential of co-targeting the Lysyl Oxidase family together with already approved cancer drugs to improve patient outcome.

Thomas Cox CCNSW Awards Evening

Dr Thomas Cox receiving the award on behalf of the team at CCNSW’s annual Research Awards Evening.

Continue reading